Metabolic Syndrome Linked to Increased Risk for Young-Onset Dementia
By Elana Gotkine HealthDay Reporter
THURSDAY, April 24, 2025 -- Metabolic syndrome (MetS) and its individual components are associated with an increased risk for young-onset dementia (YOD), according to a study published online April 23 in Neurology.
Jeong-Yoon Lee, M.D., from Soonchunhyang University Seoul Hospital in South Korea, and colleagues conducted a nationwide population-based cohort study using data from the Korean National Insurance Service to examine whether MetS, defined according to established guidelines, and its individual components increase the risk for YOD, defined as dementia diagnosis before age 65 years.
Data were included for 1,979,509 participants; 8,921 (0.45 percent) developed YOD during an average follow-up of 7.75 years. The researchers found that MetS was associated with an increased risk for all-cause YOD, Alzheimer disease, and vascular dementia (adjusted hazard ratios, 1.24, 1.12, and 1.21, respectively). There were significant interactions noted with younger age (40 to 49 versus 50 to 59 years), female sex, drinking status, obesity, and depression.
"Our findings suggest that lifestyle changes to reduce the risk of metabolic syndrome, such as eating a healthy diet, exercising regularly, maintaining a healthy weight, quitting smoking, and reducing stress, may help reduce the risk of young-onset dementia," coauthor Minwoo Lee, M.D., Ph.D., of Hallym University Sacred Heart Hospital in Anyang, South Korea, said in a statement. "Future research that follows people over longer periods of time and uses brain scans to look for biomarkers of dementia is needed to confirm and expand upon our findings."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-04-25 06:00
Read more

- Major Job Cuts at NIOSH Pose Risks to Worker Safety, Critics Warn
- FDA Removes Top Expert on Vaping and Tobacco
- Eviction Bans Linked To Drop In Child Abuse Reports
- U.S. Births Barely Rise in 2024
- Midafternoon Dosing Improves Lung Function in Atopic Asthma
- Fasting Outperforms Calorie Cutting, Clinical Trial Says
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions